NCTN Sarcoma Trials Portfolio (Open as of 9/15/2026)

Each far right box includes the NCTN protocol number with a hyperlink to the associated ClinicalTrials.gov webpage. Click on it to view the protocol title and study information.



Cross-disease trials:

EAY191 (ComboMATCH) → **Sub-study: EAY191-N5 (HER2 amplified)**

Note: * ARST2032: only available for COG sites.
^ PEPN1924: open through the COG Pediatric Early Phase Clinical Trial Network (PEP-CTN) and patients must be enrolled at one of the PEP-CTN institutions.
Ref: https://dctd.cancer.gov/research/networks/pediatric

NCTN Sarcoma Trials (Open as of 9/15/2026)

Protocol Number	Phase	Protocol Title
AOST2031	III	A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma
AOST2032	II/III	A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma
ARST2032	III	A Prospective Phase 3 Study of Patients with Newly Diagnosed Very Low-Risk and Low-Risk Fusion Negative Rhabdomyosarcoma
ARST2531	III	A Randomized Phase 3 Study to Compare VAC (Higher Cyclophosphamide Dose and Intensity) Versus VAC/VI (Lower Cyclophosphamide Dose and Intensity) Plus Maintenance Therapy in Patients with Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma
EA7211	III	A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Patients with High Risk RetroPeritoneal Sarcoma (STRASS 2)
EA7222	III	A Randomized Phase III Trial of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas
PEPN1924	II	A Phase 1/2 Study of DS-8201a (NSC# 807708) in Children, Adolescents, or Young Adults with Recurrent Osteosarcoma, Wilms Tumor, and Desmoplastic Small round Cell Tumor
S2505	III	Phase III Randomized Study Testing Non-Inferiority of Short-Course Ultra-Hypofractionated Radiation (UHRT-5) Versus Standard Fractionation (RT-25) for Stage II-IIIB, Extremity, Resectable Soft Tissue Sarcoma
EAY191	Other	Molecular Analysis for Combination Therapy Choice (ComboMATCH)
EAY191-N5	II	A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination with Palbociclib, a CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment Trial

This portfolio shows NCTN trials. For information about NCORP trials, please see: https://ncorp.cancer.gov/find-a-study/